Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Imprimir: 0893-9675
ISSN On-line: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2015013553
pages 155-171

Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?

Elizabeth Lawlor
University of Michigan
Poul H. Sorensen
Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

RESUMO

Ewing sarcoma (ES) is a highly aggressive bone and soft-tissue tumor with peak incidence among adolescents and young adults. Despite advances in local control and systemic chemotherapy, metastatic relapse after an initial clinical remission remains a significant clinical problem. In addition, metastasis at the time of presentation or at relapse continues to be the leading cause of death for patients diagnosed with ES. Since the discovery of the pathognomonic EWS−FLI1 fusion gene more than 20 years ago, much about the molecular and cellular biology of ES pathogenesis has been learned. In addition, more recent exploitation of advances in stem cell and developmental biology has provided key insights into the cellular origins of ES and the role of epigenetic deregulation in tumor initiation and maintenance. Nevertheless, the mechanisms that drive tumor relapse and metastasis remain largely unknown. These gaps in our knowledge continue to hamper the development of novel therapeutic strategies that may improve outcomes for patients with relapsed and metastatic disease. In this article we review the current status of ES biology research, highlighting areas of investigation that we consider to have the greatest potential to yield findings that will translate into clinically significant advances.


Articles with similar content:

Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Ruifang Sun, Ken H. Young, Jinfen Wang
Fibromyalgia Syndrome: Toward an Integration of the Literature
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.13, 2001, issue 1
Michael A. Ashburn, Akiko Okifuji
Cancer Stem Cells in Urooncology
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Cag Cal, Zeynep Yuce
Newer Trends in Pancreatic Cancer Treatment: Genetic Alterations and the Role of Immune Therapeutic and Targeted Therapies
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Abdul Kareem Khan, Mamoon Ur Rashid, Ishtiaq Hussain, Sarfraz Ahmad, Hasan Badar, Muhammad Muzammil, Sundas Jehanzeb, Deepika Sarvepalli, Muhammad Talha Khan, Asad ur Rahman, Waqas Ullah
Human High Molecular Weight-Melanoma-Associated Antigen (HMW-MAA): A Melanoma Cell Surface Chondroitin Sulfate Proteoglycan (MSCP) with Biological and Clinical Significance
Critical Reviews™ in Immunology, Vol.24, 2004, issue 4
Soldano Ferrone, Xinhui Wang, Toshiro Kageshita, Chien-Chung Chang, Michael R. Campoli, James B. McCarthy